公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2019 | Prognostic factors and treatment outcomes of adult patients with rhabdomyosarcoma after multimodality treatment | Liu Y.-T.; CHUN-WEI WANG ; RUEY-LONG HONG ; SUNG-HSIN KUO | Anticancer Research | 14 | 11 | |
2002 | Prognostic value of multidrug resistance 1, glutathione-S-transferase-π and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy | CHIH-HUNG HSU ; Chen C.-L.; RUEY-LONG HONG ; Chen K.-L.; Lin J.-F.; ANN-LII CHENG | Oncology | 31 | 25 | |
2003 | Quality of life in patients of nasopharyngeal carcinoma: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35 | WEI-CHU CHIE ; RUEY-LONG HONG ; Lai C.-C.; Ting L.-L.; Hsu M.-M. | Quality of Life Research | 89 | 76 | |
2017 | A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141 | Kiyota N.; Hasegawa Y.; Takahashi S.; Yokota T.; Yen C.-J.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Sum Kenneth Li W.; Ferris R.L.; Gillison M.; Namba Y.; Monga M.; Lynch M.; Tahara M. | Oral Oncology | 80 | 69 | |
2002 | Reappraisal of the new UICC staging system for gastric cancer: Problem in lymph node stage | Lee W.-J.; RUEY-LONG HONG ; I-RUE LAI ; Chen C.-N.; PO-HUANG LEE ; Chung K.-C. | Hepato-Gastroenterology | 14 | 12 | |
2004 | Recent advances in the treatment of nasopharyngeal carcinoma | Chang J.T.-C.; JENQ-YUH KO ; RUEY-LONG HONG | Journal of the Formosan Medical Association | | | |
2003 | Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma | SHANG-YI HUANG ; JIH-LUH TANG ; MING YAO ; BOR-SHENG KO ; RUEY-LONG HONG ; Tsai W.; Wang C.-H.; HWEI-FANG TIEN ; MING-CHING SHEN ; YAO-CHANG CHEN | Annals of Hematology | 12 | 10 | |
1998 | Relation between Histological Intensity of Transforming Growth Factor-β Isoforms in Human Osteosarcoma and the Rate of Lung Metastasis | RONG-SEN YANG ; CHEN-TU WU ; Lin K.-H.; RUEY-LONG HONG ; Liu T.-K.; KAI-HSIN LIN | Tohoku Journal of Experimental Medicine | 23 | 21 | |
2005 | Response of refractory osteosarcoma to thalidomide and celecoxib | YU-CHIEH TSAI ; CHEN-TU WU ; RUEY-LONG HONG | Lancet Oncology | 15 | 14 | |
2023 | Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis | Petit, Claire; Lee, Anne; Ma, Jun; Lacas, Benjamin; Ng, Wai Tong; Chan, Anthony T C; RUEY-LONG HONG ; Chen, Ming-Yuan; Chen, Lei; Li, Wen-Fei; Huang, Pei-Yu; Tan, Terence; Ngan, Roger K C; Zhu, Guopei; Mai, Hai-Qiang; Hui, Edwin P; Fountzilas, George; Zhang, Li; Carmel, Alexandra; Kwong, Dora L W; Moon, James; Bourhis, Jean; Auperin, Anne; Pignon, Jean-Pierre; Blanchard, Pierre | The Lancet. Oncology | 8 | 8 | |
2022 | Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis | HSIANG-FONG KAO ; HUAI-CHENG HUANG ; BIN-CHI LIAO ; RUEY-LONG HONG | BMC cancer | 2 | 2 | |
2002 | Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: Stability, pharmacokinetic and therapeutic evaluation | Liu J.-J.; RUEY-LONG HONG ; WEN-FANG CHENG ; Hong K.; FU-HSIUNG CHANG ; Tseng Y.-L. | Anti-Cancer Drugs | 38 | 35 | |
2022 | A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma | WEI-WU CHEN ; CHIA-LANG HSU ; RUEY-LONG HONG ; JEN-CHIEH LEE ; Chang, Koping; CHIH-WEI YU ; Chen, San-Chi; JHE-CYUAN GUO ; Chen, Mei-Lu; Hsu, Meng-Chi; Kung, Ting-Fang; ANN-LII CHENG ; Yen, Chueh-Chuan | Clinical cancer research : an official journal of the American Association for Cancer Research | 6 | 6 | |
1999 | Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model | Tseng Y.-L.; RUEY-LONG HONG ; Tao M.-H.; FU-HSIUNG CHANG | International Journal of Cancer | 62 | | |
2017 | Terminally Ill Taiwanese Cancer Patients’ and Family Caregivers’ Agreement on Patterns of Life-Sustaining Treatment Preferences Is Poor to Fair and Declines Over a Decade: Results From Two Independent Cross-Sectional Studies | Liu T.-W.; Wen F.-H.; Wang C.-H.; RUEY-LONG HONG ; Chow J.-M.; Chen J.-S.; Chiu C.-F.; Tang S.T. | Journal of Pain and Symptom Management | 17 | 16 | |
2002 | Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and Tat: A kinetic and efficacy study | Tseng Y.-L.; Liu J.-J.; RUEY-LONG HONG | Molecular Pharmacology | 218 | 205 | |
2004 | Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma | Li C.-C.; HWEI-FANG TIEN ; JIH-LUH TANG ; MING YAO ; YAO-CHANG CHEN ; Su I.-J.; Hsu S.-M.; RUEY-LONG HONG | Cancer | 168 | 142 | |
2017 | Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma | WEN-CHI YANG ; CHUN-WEI WANG ; RUEY-LONG HONG ; CHIAO-LING TSAI ; MING YAO ; JIH-LUH TANG ; CHUNG-WU LIN ; ANN-LII CHENG ; SUNG-HSIN KUO | Journal of Radiation Research | 9 | 9 | |
2020 | Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) | Yen C.-J.; Kiyota N.; Hanai N.; Takahashi S.; Yokota T.; Iwae S.; Shimizu Y.; RUEY-LONG HONG ; Goto M.; Kang J.-H.; Li W.S.K.; Ferris R.L.; Gillison M.; Endo T.; Jayaprakash V.; Tahara M. | Head and Neck | 25 | 19 | |
1998 | Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties | Zhang L.; Lau Y.-K.; Xi L.; RUEY-LONG HONG ; Kim D.S.H.L.; Chen C.-F.; Hortobagyi G.N.; Chang C.-J.; Hung M.-C. | Oncogene | 115 | 103 | |